Carisma Therapeutics, Inc. (W2J.F)
| Previous close | 1.5670 |
| Open | 1.5660 |
| Bid | 1.4550 x N/A |
| Ask | 1.5120 x N/A |
| Day's range | 1.5640 - 1.5680 |
| 52-week range | 1.5600 - 8.6000 |
| Volume | |
| Avg. volume | 219 |
| Market cap | 65.139M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4300 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksHere's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PR NewswireCarisma Therapeutics to Present at Upcoming Conferences
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:
- PR Newswire
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Carisma Therapeutics Inc. (NASDAQ: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the fourth quarter, and full year ended December 31, 2023, and provided a business update.
